An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Trial Profile

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 12 Aug 2017 Data from this and other trials (NCT00932698, NCT00963820, NCT01564537) was used to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM, results published in the Targeted Oncology
    • 25 Jun 2017 Updated efficacy and long-term safety results for patients who did not withdraw from the study in order to receive stem cell transplantation, presented at the 22nd Congress of the European Haematology Association.
    • 23 Jun 2017 According to a Takeda media release, Shaji Kumar is a lead investigator of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top